This week in AI ∩ Bio, we look at “Proteome-wide model for human disease genetics”, which introduces popEVE, an unsupervised model for prioritizing missense variants across the human proteome.
The key idea: give each amino-acid change a calibrated severity score based on how evolutionarily and statistically “intolerant” it looks, without pretending to directly predict pathogenicity. But even though the model is not trained on pathogenicity, the scores it produces are correlated with pathogenicity, and often clustered in biologically plausible regions.
Scientific Insight
popEVE combines two sequence-based models (EVE and ESM-1v) with real-world human variation from ~460,000 genomes (UK Biobank + gnomAD).
EVE and ESM-1v together give a composite view of how “acceptable” a variant is:
- EVE is a variational autoencoder trained on multiple sequence alignments (MSAs) across species. It captures deep evolutionary conservation
- ESM is a large-scale unsupervised transformer model trained on unlabeled protein sequences. It captures local structural and biophysical coherence
They are combined (with some weighting) into a raw deleteriousness score per variant.
Then, they look at Human Variant Depletion: Presence/Absence in gnomAD/UKBB, which provides empirical evidence of human constraint.
For each protein position, they ask:
“Across 460,000 people, how many unique missense variants were observed here?”
If a position has:
- Many unique variants → assumed tolerant in humans
- Few or no variants → suggests purifying selection, i.e., likely deleterious if mutated
They feed this site-level variant density into a Gaussian Process calibration layer, which:
- Adjusts the EVE+ESM score to reflect gene-specific constraint
- Produces a calibrated score that is comparable across genes
The resulting score correlates with disease severity and clusters in known functional domains and interfaces, and in singleton diagnostic cases, ~80% of truly causal variants land in the model’s top 10 candidates.
Importantly, the authors are clear about limits: no non-coding variants, no epistasis or tissue context, and potential confounding from sequencing and coverage artifacts.
Leadership Angle
For diagnostics leaders, popEVE is a tool for smarter triage, not a final verdict.
It offers a transparent, cross-gene notion of constraint that can sharpen variant review in rare disease and carrier screening workflows, if we remember exactly what it measures: statistical intolerance, not clinical truth.
Mentorship Angle
For early-career scientists, this paper demonstrates disciplined scope and thoughtful integration.
The authors explicitly state what popEVE does not do, then show where its scores line up with known biology and clinical patterns.
If you’re building a career in biotech, this is the sweet spot: models that are powerful because you understand the biology, the data generation, and the limits of what any score can tell you about a real patient.
Skip to PDF content